Affiliations: [a] Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, TX 77555, USA | [b] PharmaReview Corporation, Pearland, TX 77584, USA
Correspondence:
[*]
Corresponding author: Marian L. Kruzel, Ph.D., PharmaReview Corporation, 2605 Brightlake Way Ln., Pearland, TX 77584, USA. Tel.: +1 713 340 0447; Fax: +1 713 340 0442; E-mail: [email protected].
Abstract: Colostrum-derived proline-rich polypeptide, also known as Colostrinin™ (CLN), has been shown to have a stabilizing effect on cognitive function in Alzheimer's disease patients. This complex action of CLN could be related to prevention of amyloid-β peptide aggregation, as shown in in vitro studies, and its impact on delicate cassettes of signaling pathways common to cellular redox regulation, proliferation and differentiation. Studies on cultured cells showed that CLN modulates intracellular levels of reactive oxygen species (ROS), via regulation of glutathione metabolism, activity of antioxidant enzymes and mitochondria function. Due to an improvement in senescence-associated mitochondrial dysfunction and a decrease in ROS generation, CLN decelerates the aging processes of both cultured cells and experimental animals. When given orally to mice, CLN increased the lifespan and improved various motor and sensory activities. Although the molecular basis by which CLN exerts its diverse effects are still under investigation, the regulatory effect on the cellular redox state via maintenance of mitochondrial function and modification of ROS-induced cell signaling seem to be of great importance. In this article, we examine experimental data pertinent to the mechanism of action, including a review of CLN's utility in the maintenance of physiological processes in which oxidative stress has an etiological role.
